News
Market and company headlines
GILDAll
Loading
02:00Oct 241 Story
13:00-21:00Oct 232 Stories
Stocktwits Biotech Dealmaker: Gilead And Roche Double Down On Early-Stage Assets Over Full Buyouts This Week
Inflammation, cancer therapies called antibody-drug conjugates, and next-generation T-cell engagers with possibilities in treating cancer drew the biggest capital in the relatively slow week for biotech dealmaking.
The Lanier Law Firm Supports Attorney General Ken Paxton in Reaching $45 Million Settlement with Gilead in Unlawful Inducement Scheme
HOUSTON, October 23, 2026--Building on decades of holding pharmaceutical companies responsible for dangerous products and unlawful business practices, The Lanier Law Firm played a pivotal role supporting Texas Attorney General Ken Paxton in securing a $45 million settlement with Gilead Sciences, Inc. Announced on Oct. 22, the settlement resolves claims that the company offered illegal incentives to medical providers to prescribe its drugs over competitors’ medications.
08:00Oct 231 Story
16:00Oct 222 Stories
Gilead Sciences (GILD) vs. AMGN and VRTX: Can Oncology Growth and HIV Strength Drive a New Growth Era Beyond Acquisitions?
Is GILD a good stock to buy? We came across a bullish thesis on Gilead Sciences, Inc. on Astute Optics – US’s Substack. In this article, we will summarize the bulls’ thesis on GILD. Gilead Sciences, Inc.’s share was trading at $156.51 as of October 20th 2026. GILD’s trailing and forward P/E were 17.84 and 15.55 respectively […]
Gilead to Acquire Investigational Oral IL-23R Inhibitor HCXT-2001, Strengthening Its Inflammation Pipeline in IBD
FOSTER CITY, Calif., October 22, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire an oral IL-23R inhibitor program, including lead asset HCXT-2001, from PepStar Therapeutics Limited, a privately held, clinical-stage biotechnology company.
09:00-13:00Oct 222 Stories
Gilead Sciences Agrees To Acquire Oral IL-23R Inhibitor Program From PepStar Therapeutics Under $1.275B Deal
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire an oral IL-23R inhibitor program, including lead asset HCXT-2001, from PepStar Therapeutics Limited, a
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
06:00-09:00Oct 222 Stories
Gilead to Present New Data on Treatment Response and Long-Term Management of Rare Liver Diseases at The Liver Meeting® 2026
FOSTER CITY, Calif., October 22, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) will present new clinical and real-world evidence across primary biliary cholangitis (PBC) and chronic hepatitis delta virus (HDV) infection at The Liver Meeting® 2026, hosted by the American Association for the Study of Liver Diseases (AASLD), November 5-9 in Denver, Colorado. The data will examine durability of response, patient-relevant symptoms, and opportunities to better understand long-term disease management acro
BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead’s TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer
BioNTech enters a clinical trial collaboration with Gilead Sciences with the aim of improving outcomes in patients with PD-L1 low or negative triple-negative breast cancerThe global Phase 3 ROSETTA Breast-01 trial will evolve to evaluate pumitamig in combination with sacituzumab govitecan, a TROP2-directed antibody-drug conjugate, reflecting the new standard of care in first-line treatment of metastatic triple-negative breast cancer This will be the first global Phase 3 trial of pumitamig in com
17:00Oct 211 Story
00:00-03:00Oct 202 Stories
B of A Securities Maintains Buy on Gilead Sciences, Raises Price Target to $172
B of A Securities analyst Tim Anderson maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $168 to $172.
How Investors Are Reacting To Gilead Sciences (GILD) FDA Drug Approvals
Gilead Sciences recently secured multiple FDA decisions, including approval for the Bixlenvo HIV regimen, a label expansion for Trodelvy in first line metastatic triple negative breast cancer, and approval for Hepcludex for chronic hepatitis delta. The company is also preparing to share new data across HIV and antiviral programs at IDWeek 2026. These regulatory milestones arrive as Gilead Sciences absorbs acquired research costs that led to a reported US$3.24b loss over the twelve months to...
11:00Oct 192 Stories
What Has Changed About Owning Gilead Stock?
Investors holding Gilead Sciences (GILD) likely bought into a steady profit engine. The company relies on HIV drugs, led by Biktarvy, to earn money year after year and fund a reliable dividend. Gilead spent the first half of 2026 acquiring other businesses, including Arcellx and Tubulis, before reporting its fiscal second quarter on August 4, 2026. What did those deals do to the profit you were counting on.
All You Need to Know About Gilead (GILD) Rating Upgrade to Buy
Gilead (GILD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
08:00-11:00Oct 192 Stories
Gilead Bolsters Inflammatory Bowel Disease Pipeline With Promising Mid-Stage Trial Success
Gilead Sciences announced positive Phase 2 SWIFT trial results for emvistegrast, an oral treatment for active ulcerative colitis.
Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026
FOSTER CITY, Calif., October 19, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) will present new findings from its HIV and antiviral research and development programs at IDWeek 2026, taking place October 21-24 in Washington, D.C. The 28 presentations, including two oral presentations, will feature research in HIV treatment, HIV prevention and new insights into broader experiences of people living with HIV, as well as emerging antiviral programs.
02:00Oct 191 Story
13:00Oct 181 Story
19:00-21:00Oct 162 Stories
Gilead’s HIV Prevention Business Just Topped $1 Billion A Quarter. What Comes Next?
Gilead Sciences (GILD) built its foundation on HIV treatment. Biktarvy alone accounted for $14.3 billion of the company's $29.4 billion in fiscal 2025 revenue. Yet another segment of the HIV business is growing at a much faster pace, and it targets people who do not currently carry the virus. Gilead expects a regulatory decision regarding a new option in this category in early 2027. So what is that business, and how much is it selling today.
Stocktwits Biotech Dealmaker: Gilead, AstraZeneca And Roche Chase Pipeline Expansion Over Buyouts
Deals for AI discovery platforms and differentiated experimental candidates for obesity and solid tumors dominated the week.
16:00-18:00Oct 153 Stories
Gilead Sciences (GILD) Rises Higher Than Market: Key Facts
Gilead Sciences (GILD) closed the most recent trading day at $157.48, moving +2.57% from the previous trading session.
Gilead and Cardinal Health Stocks Jump to Record Highs. Why Healthcare Is on a Tear.
AbbVie, meanwhile, closed just shy of a record high, with shares ticking up 0.6% to $283.40.
Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
FOSTER CITY, Calif., October 15, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2026 financial results and guidance will be released on Thursday, October 29, 2026 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s third quarter 2026 financial results and provide a business update.
13:00-15:00Oct 152 Stories
Final Trade: AEM, IEV, BABA, GILD
The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.
Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth?
Gilead Sciences expands its oncology pipeline through a Vir Biotechnology deal worth up to $1.74 billion in additional milestones, targeting three novel cancer therapies.
08:00-11:00Oct 152 Stories
Gilead and Vir forge $1.9bn pact to develop next-gen T-cell engagers
This deal sees Gilead double down on TCEs, following its first bet on the modality through its March buyout of autoimmune-focused Ouro Medicines.
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
09:00-14:00Oct 142 Stories
What Does Gilead Sciences (GILD) Gain From Its New Solid Tumor Partnership?
Gilead Sciences (NasdaqGS:GILD) announced a collaboration with Vir Biotechnology to develop novel T cell engagers for solid tumors. The agreement grants Gilead exclusive rights to further develop and commercialize T cell engager candidates using Vir's technology platform. Vir's expertise in immunology and antibody engineering will be applied to create targeted therapies aimed at patients with solid tumor cancers. The new Gilead and Vir T cell engager collaboration for solid tumors is an...
Vir Biotechnology, Gilead Sciences to Develop Dual-Masked T-Cell Engagers for Solid Tumors
Vir Biotechnology (VIR) has signed a collaboration and license agreement with Gilead Sciences (GILD)
16:00-21:00Oct 122 Stories
Biogen (BIIB) vs Amgen (AMGN) and Gilead (GILD): Which Big Pharma Stock is a Better Buy?
Biogen Inc. (NASDAQ:BIIB) closed at $225.71 on October 9. The stock has returned 30.5% during the last six months, compared to a 24.3% return for the Insider Monkey Billionaire Index and 15.1% for the State Street SPDR S&P 500 ETF Trust. Amgen Inc. (NASDAQ:AMGN) closed at $414.87 and has returned 18.6% over the same six […]
Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Dosed first patient in registrational Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in relapsed/refractory CLL/SLL Advanced bexobrutideg combination strategy with initiation of recruiting for the Phase 1b/2 NX-5948-203 study Earned $27M from Gilead, Pfizer and Sanofi collaborations, including a $10M milestone from Sanofi for first patient dosed in the STAT6 degrader Phase 1 trial Advanced NX-1607 into Phase 1b expansion cohorts in MSS CRC, NSCLC, CRPC and melanoma with
09:00-12:00Oct 122 Stories
Gilead Sciences' Yeztugo Survey Supports Long-Term Growth Outlook, BofA Says
Gilead Sciences' (GILD) HIV prevention drug Yeztugo's long-term growth outlook is supported by a phy
Can Gilead (GILD) Stock Continue Rising in 2027?
Gilead Sciences, Inc. (NASDAQ:GILD) shares are up more than 24% this year, ahead of the S&P 500’s 14%. Gilead makes HIV, liver disease and cancer drugs. The stock is part of our coverage of the 8 best-performing stock picks by Claude AI in 2026. Why Gilead Stock Is Up Gilead Q2 sales rose 10% year […]
02:00-10:00Oct 112 Stories
Gilead Has Outperformed the S&P 500. But is its Valuation Still Attractive?
Gilead Sciences, Inc. (NASDAQ:GILD) has had a considerably better year than the broader market. The stock has surged by over 24% since the start of the year, compared with a 14% return for the S&P 500. The rally has changed the valuation equation. Yahoo Finance recently put Gilead’s normalized forward P/E at approximately 15.5 times. […]
Is Gilead Sciences (GILD) Undervalued After Strong Q2 Sales?
Gilead Sciences stock has delivered a strong multi year run, which puts a spotlight on whether the current share price still lines up with the company’s sales base. With fresh headlines on earnings, partnerships and pipeline progress, the real question for investors is how much of Gilead’s revenue story is already reflected in today’s valuation. Over the past 5 years, Gilead Sciences has returned 167.1%. Anyone looking at the stock now is asking how that kind of gain squares with its sales...
17:00-21:00Oct 92 Stories
Why Is Everyone Ignoring Gilead Stock's High Cash Yield?
Gilead Sciences (GILD) generated free cash flow equal to 7.1% of its market value over the last twelve months. The median S&P 500 company yielded just 4.5% over the same period. A yield that high means one of two things: the business is either trading at a steep discount, or the market expects it to shrink. So why are investors paying so little for Gilead's cash.
Gilead Sciences (GILD) Laps the Stock Market: Here's Why
Gilead Sciences (GILD) closed the most recent trading day at $151.17, moving +2.77% from the previous trading session.
06:00Oct 61 Story
07:00Oct 52 Stories
Gilead Sciences (NASDAQ:GILD) Offers Dividend Investors Quality Income and Valuation Support
Gilead Sciences (GILD) passes a high-quality dividend screen with a 3.98% yield, strong profitability, cheap valuation, and key risks to watch.
Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences
Two-year extension builds on productive relationship established in 2019 Nurix continues to retain co-development and 50/50 profit sharing options on up to two programs in the United States BRISBANE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Nurix and Gilead Sciences have agreed to extend th
03:00Oct 51 Story
06:00-17:00Oct 22 Stories
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
Gilead Sciences (GILD) closed the most recent trading day at $144.74, moving 1.87% from the previous trading session.
Gilead Sciences (NASDAQ:GILD) Combines Top Technical Strength With a High-Quality Breakout Setup
Gilead Sciences (GILD) earns a 10/10 Technical Rating and 8/10 Setup Quality on ChartMill's breakout screen. See entry, stop, and risk levels.
08:00-23:00Oct 12 Stories
More Upside Awaits for Gilead Sciences Stock. Stay Invested.
Gilead shares are up 35% since Barron’s highlighted them, but our catalysts have yet to fully play out.
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
17:00Sep 301 Story
05:00-10:00Sep 292 Stories
Former Gilead CIO and CSL Chief Digital & Information Officer Mark Hill Joins Sware Board of Directors
BOSTON, September 29, 2026--Sware, Inc., the company behind the Res_Q, the AI-powered validation platform, and provider of GxP compliance solutions, today announced the appointment of Mark Hill to its Board of Directors.
Small Molecule Drug Discovery - Global Strategic Business Report Forecasts Growth from $61.5B (2024) to $100B by 2030, Profiling AstraZeneca, Gilead Sciences, Merck & Pfizer
AI, computational design and high-throughput screening are accelerating discovery, while targeted therapies, outsourcing and Asia-Pacific expansion create opportunities.Dublin, Sept. 29, 2026 (GLOBE NEWSWIRE) -- "Small Molecule Drug Discovery - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global small molecule drug discovery market was valued at US$61.5 billion in 2024 and is projected to reach US$100 billion by 2030, expanding at a compound annual g
15:00-20:00Sep 282 Stories
Can Lenacapavir Power Gilead Sciences (GILD)’s Next Growth Phase?
On September 16, Gilead Sciences, Inc. (NASDAQ:GILD) expanded the scope of its six royalty-free voluntary licensing agreements for lenacapavir to cover an investigational once-yearly formulation for HIV pre-exposure prophylaxis (PrEP). Covering 120 high-incidence, lower-income countries, the expanded framework aims to accelerate manufacturing readiness and technology transfer during the ongoing Phase 3 PURPOSE 365 study. Following […]
Gilead vs. Intuitive Surgical: Which Healthcare Stock Offers the Better Risk-Adjusted Upside?
At first glance, Gilead Sciences, Inc. (NASDAQ:GILD) and Intuitive Surgical, Inc. (NASDAQ:ISRG) don’t make for the most obvious comparison. One sells medicines led by a massive HIV franchise, while the other has built its business around robotic surgery. Yet both have given investors a similar reason to pay attention this year, which is that growth […]
09:00-15:00Sep 282 Stories
Gilead vs. Thermo Fisher: Which Life Sciences Stock has the Stronger Growth Outlook?
Gilead Sciences, Inc. (NASDAQ:GILD) and Thermo Fisher Scientific Inc. (NYSE:TMO) are benefiting from two very different sources of growth. Gilead’s momentum is being driven primarily by its HIV portfolio, where established medicines and newer products are expanding rapidly. Thermo Fisher, meanwhile, is beginning to benefit from strengthening customer activity across the life-sciences markets it serves […]
Can Gilead Sciences (GILD) Justify Its Price As It Raises 2026 Guidance And Dividend?
Gilead Sciences (GILD) has put fresh numbers on the table, raising its 2026 sales outlook and lifting its quarterly dividend by 3.8%, a combination that tends to grab investor attention. That guidance change is landing in a stock that already has momentum behind it, with a 90 day share price return of 19.46% and a year to date move of 24.12%. Over the longer haul, Gilead Sciences has delivered a 37.33% 1 year total shareholder return and triple digit total shareholder returns over 3 and 5...
05:00-19:00Sep 222 Stories
Gilead Sciences (GILD) Stock Moves 1.40%: What You Should Know
Gilead Sciences (GILD) closed the most recent trading day at $152.67, moving +1.4% from the previous trading session.
1 Cash-Producing Stock on Our Buy List and 2 We Find Risky
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
08:00-12:00Sep 212 Stories
BMY vs GILD: Which Biotech Stock Looks More Attractive Now?
Bristol Myers' growth portfolio and pipeline advances offer multiple ways to offset legacy-product erosion, while valuation and leverage remain key factors.
Novo Nordisk Stock Drops 5.6% as 2030 Goals Match Peers
The drugmaker expects growth in line with industry peers as it works to rebuild its pipeline beyond obesity